Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1)
- Target
- GABARAPL1
- Molecular classification
- Ubiquitin-like modifier, Autophagy-related protein, Trafficking-associated protein, Other
01
Overview
Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1) is a ubiquitin-like protein involved in autophagy and receptor trafficking. Highly conserved across species, it belongs to the GABARAP/Atg8 protein family and is essential for autophagic vacuole formation and regulation of mitochondrial quality. GABARAPL1 interacts with the GABA(A) receptor and kappa opioid receptor, modulating their trafficking to the plasma membrane[1][2][3][4]. Experimentally, decreased GABARAPL1 impairs autophagic flux, increases cell proliferation and invasion (notably in breast cancer models), and disturbs mitochondrial homeostasis[1]. GABARAPL1 also plays a tumor suppressor role, and its reduced expression is linked to more aggressive cellular phenotypes and altered mitochondrial metabolism in certain cancers[1]. Additionally, changes in GABARAPL1 expression are observed in neurodegenerative and muscular diseases, reflecting its role in cellular response to stress and protein/organelle turnover[1][4]. No clinical drugs directly target GABARAPL1 at this time, but the protein represents a key node in autophagy regulation and disease-related cellular processes.
- Other names
- GEC1APG8LATG8LATG8BEarly estrogen-regulated proteinGABA(A) receptor-associated protein-like 1Glandular epithelial cell protein 1APG8-LIKEATG8GEC-1gec1
02
Mechanism of action
Not drug-targeted at present; biologically, modulates receptor trafficking and autophagic degradation
03
Biological functions
Autophagy (specifically macroautophagy and autophagic flux)Receptor trafficking (notably of GABA(A) and kappa opioid receptors)Regulation of cell proliferation and invasionMitochondrial homeostasis and metabolismMicrotubule binding and assembly
04
Disease associations
Cancer (tumor suppressor in breast cancer)Neurodegenerative disease (e.g., altered in Parkinson disease)Muscular disease (e.g., reduced in Duchenne muscular dystrophy)Other (potential roles in additional pathologies due to altered autophagy)
05
Safety considerations
Not applicable due to lack of direct drug targeting; potential challenges if targeted could relate to perturbation of autophagy or mitochondrial homeostasis
06
Biomarkers
Low expression in breast cancer may indicate worse prognosisAltered expression in neurodegenerative and muscle diseases may serve as a marker
Beyond the preview
Go deeper on Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1).